# Merck invests over €300M in new bioprocessing production center in Daejeon, South Korea

Merck, through its Life Science business sector, is investing more than €300 million in a new Bioprocessing Production Center in Daejeon, South Korea, expected to create approximately 300 additional jobs by the end of 2028.

- Type: New facility
- Announced: 2024-03-20
- Where: Daejeon, South Korea
- Value: $325.0M (300.0M EUR)
- Jobs: 300
- Starts operating: 2028
- Status: announced
- Products: dry powder cell culture media, process liquids, pre-GMP small-scale manufacturing, sterile sampling systems
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Merck](https://endata.com/companies/1841.md)

## Sources

- [sigmaaldrich.com](https://www.sigmaaldrich.com/LT/en/collections/press/bioprocessing-production-center-in-daejeon-south-korea), 2024-03-20: "Expanding our presence in the region will bring us even closer to our customers in this evolving and dynamic market."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.